library.onepin.app/bpc-157 Peptide Education Library
Education only, not medical advice 21+ Every dose is an example to finalize with a licensed provider

OnePin Peptide Library · Repair & Recovery

Repair & Recovery Gastric Pentadecapeptide Not FDA-approved · investigational

BPC-157

Body Protection Compound · Pentadecapeptide BPC

Gastric PentadecapeptideTissue RepairCytoprotectiveAnti-inflammatory

Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide (15 amino acids) derived from a protective protein found in human gastric juice. The sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) is stable in gastric acid, unlike most peptides.

Quick Start
Route
Subcutaneous (SubQ) injection
Start low
250mcg
Frequency
1-2x daily
Timing
No fasting required

Can be taken any time. For injury healing, inject near the injury site. Morning and evening dosing (split) may improve outcomes. No fasting required for SubQ. Empty stomach for oral.

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first
Quick Start
Conservative start
250mcg · Subcutaneous (SubQ) injection · 1-2x daily
Lowest starting point. Hold about a week to assess tolerance before stepping up.
250mcg
1-2x daily
Standard
Standard Healing
250-500 mcg · SubQ · Daily
animal study · Sikiric et al. 2010 (Curr Pharm Des, 16(10):1224-34)
250-500 mcg
Daily
Intermediate
Systemic Twice-Daily
250 mcg per dose · SubQ · 2x Daily
anecdotal · community
250 mcg per dose
2x Daily
Reconstitution CalculatorU-100
050100u
Draw to
units
01

How it works

BPC-157 works through multiple complementary mechanisms:

Angiogenesis

Upregulates VEGF (vascular endothelial growth factor) and eNOS, promoting new blood vessel formation at injury sites. This increases nutrient and oxygen delivery to damaged tissue.

NO System Modulation

Acts as a stabilizer of the nitric oxide system, which regulates blood flow, inflammation, and cellular signaling. Unlike simple NO boosters, BPC-157 appears to normalize the system in both directions.

GH Receptor Upregulation

Increases growth hormone receptor expression in target tissues, amplifying the repair effects of both endogenous and exogenous growth hormone.

FAK-Paxillin Pathway

Activates focal adhesion kinase signaling, which drives cell migration to injury sites - a critical early step in tissue repair.

Collagen Synthesis

Promotes fibroblast activity and organized collagen deposition, supporting structural repair rather than scar formation.

Gut-Brain Axis

Interacts with the dopaminergic and serotonergic systems, which may explain its protective effects on both the GI tract and central nervous system.

02

What to expect

Early
Days 1–7

Days 1-7: Reduced inflammation and pain at injury site. Some users report noticeable improvement within 48 hours for acute injuries. Gut issues may show early relief. Injection site may have brief warmth or redness.

Mid
Weeks 2–4

Weeks 2-4: Significant healing progress. Chronic injuries begin responding. Tendon and ligament pain markedly reduced. Gut permeability improving. Range of motion and function returning. This is where most users report the most dramatic changes.

Later
Weeks 4–12

Weeks 4-12: Structural repair consolidating. Chronic issues that took months to develop may need this longer timeframe. Collagen remodeling continuing. Some users continue at maintenance dose. Consider cycling off after 8-12 weeks.

03

Evidence

HumanNo published trials
AnimalStrong
In-vitroPresent
2021Stable Gastric Pentadecapeptide BPC 157 and Wound Healing · Sikiric P et al, Frontiers in Pharmacology ↗review
2015Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro · Huang T et al, Drug Design, Development and Therapy ↗peer reviewed
2011The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration · Chang CH et al, Journal of Applied Physiology ↗peer reviewed
2025Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing · Park CH et al, HSS Journal ↗review
04

The honest take

BPC-157 can heal any injury

Overstated

Overstated. Animal studies show broad tissue repair capability, but 'any injury' is too absolute. It accelerates natural healing processes - it doesn't regenerate completely destroyed tissue. Structural tears may still need surgical intervention.

Works in 24-48 hours
Partly true

Partially true for acute injuries and pain reduction. Some users report rapid anti-inflammatory effects. However, structural healing (tendon, ligament, collagen) takes weeks regardless of BPC-157 use. It accelerates the timeline, not eliminates it.

No side effects
Mostly fair

Mostly accurate based on available evidence. Animal studies show remarkably clean safety profile with no established LD50. However, absence of evidence is not evidence of absence - long-term human safety data simply doesn't exist yet.

05

Interactions & stacking

What's safe to combine, and what belongs in a separate pin.

Safe & synergistic

TB-500Wolverine Stack: BPC drives angiogenesis/NO, TB drives actin/cell migration. Most popular repair combination.
GHK-CuSAFE TO MIX. BPC-157 (GEPPPGKPADDAGLV) has no Met/Trp/Cys - no copper oxidation risk. BPC tissue repair + GHK-Cu collagen remodeling. GLOW blend foundation. Draw GHK-Cu last.
KPVBPC targets tissue repair via NO/VEGF, KPV targets inflammation via NF-kB. Gut healing combo.
IpamorelinBPC upregulates GH receptor expression, amplifying Ipamorelin's GH release for enhanced repair.

Keep separate

CJC-1295 with DACDAC maleimide group may react with BPC in syringe. Pin CJC-DAC separately.
NAD+Acidic pH of NAD+ can denature BPC-157. Different routes anyway (NAD+ is IM).
GlutathioneThiol chemistry may interfere. Pin separately (Glutathione is IM).
06

Side effects & safety

Commonly reported

  • Mild injection site redness or warmth (resolves in minutes)
  • Occasional lightheadedness immediately post-injection
  • Mild GI changes during gut healing (temporary)

Less common & notes

  • Rarely reported: mild headache, fatigue in first few days, temporary nausea.
  • BPC-157 has an exceptionally favorable safety profile in animal studies - no LD50 has been established because researchers could not find a lethal dose.
  • However, long-term human safety data does not exist.
07

Pharmacokinetics

Illustrative plasma concentration · 24 h
Half-life
4h
Peak · Tmax
1h
Elimination
20h
Activity
12-24 hours (VEGF/eNOS and NO system modulation persist beyond plasma clearance)

Storage. Reconstitute with bacteriostatic water. Store refrigerated at 2-8°C. Highly stable peptide - resistant to degradation, acid-stable. Shelf life 28-30 days after reconstitution. Do not freeze after reconstitution. Protect from prolonged light exposure. Slight yellow tint is normal and does not indicate degradation. Discard if cloudy or particulate matter visible.

08

Regulatory status

Not FDA-approved for any indication. Granted FDA Orphan Drug Designation for short bowel syndrome (Trials Pharma). Available through compounding pharmacies with prescription in some jurisdictions and through research chemical suppliers. Clinical trials initiated but not yet published. All current human use is experimental/off-label. Classified as a research peptide in most countries.

Put it to work

Calculate, log & track

Open BPC-157 straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open BPC-157 in the app →

Go deeper

The guide & community

The complete BPC-157 walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗
Open in app Community